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Abstract
Introduction  and  aim:  The  role  of  serum  albumin  level  in  patients  with  non-variceal  upper  gas-
trointestinal  bleeding  (NVUGB)  has  not  been  extensively  studied.  Our  aim  was  to  evaluate  the
role of  serum  albumin  on  admission  in  terms  of  in-hospital  mortality  in  patients  with  NVUGB.
Materials and  methods:  Patients  admitted  with  NVUGB  during  a  4-year  period  were  prospec-
tively included.  Demographic,  clinical,  and  laboratory  data  were  collected.  ROC  curve  analysis
was used  to  determine  the  cutoff  value  for  serum  albumin  on  admission  that  made  a  distinction
between  deceased  patients  and  survivors  with  respect  to  serum  albumin  on  admission,  as  well
as its  overall  performance  compared  with  the  Rockall  score.
Results:  185  patients  with  NVUGB  were  evaluated.  Men  predominated  (56.7%)  and  a  mean
age of  59.1  ±  19.9  years  was  found.  Mean  serum  albumin  on  admission  was  2.9  ±  0.9  g/dl  with
hypoalbuminemia  (<  3.5  g/dl)  detected  on  admission  in  71.4%  of  cases.  The  ROC  curve  found
that the  best  value  for  predicting  hospital  mortality  was  an  albumin  level  of  3.1  g/dl  (AUROC
0.738). Mortality  in  patients  with  albumin  ≥  3.2  g/dl  was  1.2%  compared  with  11.2%  in  patients
with albumin  <  3.2  g/dl  (P=.009;  OR  9.7,  95%CI  1.2-76.5).  There  was  no  difference  in  overall
performance  between  the  albumin  level  (AUORC  0.738)  and  the  Rockall  score  (AUROC  0.715)
for identifying  mortality.
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Conclusions:  Patients  with  hypoalbuminemia  presenting  with  NVUGB  have  a  greater  in-hospital
mortality rate.  The  serum  albumin  level  and  the  Rockall  score  perform  equally  in  regard  to
identifying  the  mortality  rate.
©  2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Resumen
Introducción  y  objetivo: El  papel  de  los  niveles  séricos  de  albúmina  en  pacientes  con  sangrado
de tubo  digestivo  alto  no  variceal  (SDA-NV)  no  ha  sido  estudiado  ampliamente.  Nuestro  objetivo
fue evaluar  el  papel  de  los  niveles  de  albúmina  en  la  mortalidad  de  pacientes  con  SDA-NV.
Material y  métodos:  Se  incluyó  a  pacientes  con  SDA-NV  de  forma  prospectiva  durante  un  pe-
riodo de  4  an˜os.  Se  recolectaron  datos  demográﬁcos,  clínicos  y  de  laboratorio.  Se  usó  análisis
ROC para  determinar  el  mejor  punto  de  corte  para  la  albúmina  sérica  al  momento  de  admisión
que discrimine  entre  aquellos  que  sobrevivieron  y  aquellos  que  fallecieron,  así  como  para
comparar el  desempen˜o  global  con  la  escala  de  Rockall.
Resultados:  Ciento  ochenta  y  cinco  pacientes  con  SDA-NV  fueron  analizados.  El  sexo  masculino
predominó  (56.7%)  y  la  edad  media  fue  de  59.1  ±  19.9  an˜os.  La  media  de  albúmina  al  momento
de admisión  fue  de  2.9  ±  0.9  g/dl,  detectando  hipoalbuminemia  (<  3.5  g/dl)  en  el  71.4%  de  los
casos. La  curva  ROC  encontró  un  nivel  de  albúmina  de  3.1  g/dl  (AUROC  0.738)  como  el  mejor
punto de  corte  que  predice  mortalidad  hospitalaria.  La  mortalidad  en  pacientes  con  albúmina
≥ 3.2  g/dl  fue  del  1.2%  comparado  con  el  11.2%  en  el  grupo  con  un  valor  <  3.2  g/dl  (p  =  0.009;
RM 9.7,  IC  del  95%,  1.2-76.5).  El  desempen˜o  global  para  identiﬁcar  mortalidad  fue  similar  entre
albúmina  (AUORC  0.738)  y  la  escala  de  Rockall  (AUROC  0.715).
Conclusiones:  Los  pacientes  con  SDA-NV  con  hipoalbuminemia  presentan  una  mayor  mortalidad
hospitalaria.  La  albúmina  sérica  y  la  escala  de  Rockall  mostraron  un  rendimiento  similar  para
identiﬁcar mortalidad.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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wntroduction and aim
astrointestinal  bleeding  is  a  common  medical  emergency
ith  an  estimated  incidence  of  48  to  160  events  per
00,000  adults,  accounting  for  approximately  300,000  hos-
ital  admissions  per  year  in  the  United  States.1--3 Despite
ajor  advances  in  the  management  of  non-variceal  upper
astrointestinal  bleeding  (NVUGB)  in  the  last  decades,  its
elated  mortality  rate  continues  to  be  considerable  at  5  to
0%.4,5 Peptic  ulcer  bleeding  is  still  the  most  common  cause
nd  is  responsible  for  approximately  31  to  67%  of  all  cases,
ollowed  by  erosive  disease,  esophagitis,  malignancy,  and
allory-Weiss  tears.3
Different  studies  have  shown  that  serum  albumin  levels
ave  prognostic  value  for  clinical  complications  in  differ-
nt  scenarios  including  elective  surgery,  surgical  oncology,
ospital  stay  in  patients  admitted  to  internal  medicine
r  pediatrics,  hospital  mortality  in  stroke  patients  and
f
i
satients  with  major  trauma,  among  other  conditions.6--8
espite  the  prognostic  value  of  serum  albumin  in  differ-
nt  settings,  its  clinical  value  in  patients  with  NVUGB
as  not  been  widely  evaluated  in  prospective  studies.9
e  previously  evaluated  a  cohort  of  1,067  patients  and
ound  that  the  serum  albumin  level  upon  admission  was
n  independent  predictor  of  in-hospital  mortality.10 We
lso  analyzed  a  group  of  patients  with  chronic  liver  dis-
ase  (CLD)  and  NVUGB,  and  again,  hypoalbuminemia  was
n  independent  predictor  of  mortality.4 However,  the
reviously  mentioned  studies  included  patients  with  comor-
idities  such  as  CLD,  end-stage  chronic  renal  disease
ESRD),  and  neoplasia,  which  have  been  clearly  associated
ith  hypoalbuminemia.11--13 These  entities  are  confounding
actors  associated  with  ﬁnal  outcomes  in  these  stud-
es.In this  prospective  study,  we  sought  to  examine  the  role  of
erum  albumin  upon  admission  in  relation  to  clinical  course
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and  in-hospital  mortality  in  patients  with  NVUGB  with  no
related  CLD,  ESRD,  or  neoplasia.
Materials and  methods
All  patients  admitted  to  our  hospital  with  NVUGB  during
the  period  of  August  2010  to  August  2014  were  evalu-
ated.  Inclusion  criteria  were  adult  patients  with  conﬁrmed
NVUGB  receiving  endoscopic  therapy  within  the  ﬁrst  24  h of
admission.  Patients  that  met  the  established  criteria  were
prospectively  recorded  in  a  database.  We  excluded  patients
transferred  to  another  institution  before  completing  follow-
up,  patients  with  CLD,  ESRD  (on  dialysis  or  not),  those  with
neoplasia  as  a  cause  of  bleeding,  or  patients  with  the  pres-
ence  of  cancer  at  another  site.
Variables  studied
Information  on  the  following  variables  was  collected:  demo-
graphics  (age  and  sex),  a  previous  history  of  gastrointestinal
bleeding,  and  the  use  of  nonsteroidal  antiinﬂammatory
drugs.  We  considered  the  presence  of  severe  comorbidities,
such  as  diabetes  mellitus,  cardiovascular  disease  (including
high  blood  pressure,  cerebrovascular  disease,  or  myocardial
ischemia),  chronic  obstructive  pulmonary  disease,  and  sta-
ble  nephropathy  excluding  patients  with  ESRD.  Data  related
to  the  severity  of  bleeding,  laboratory  results  upon  admis-
sion  (hemoglobin,  serum  albumin,  blood  urea  nitrogen,
and  creatinine),  need  for  transfusion  and  the  number  of
units  transfused,  and  the  use  of  proton  pump  inhibitors
and/or  H2  receptor  antagonists  were  included.  Albumin
determination  was  performed  in  a  UniCel® DxC  800  Syn-
chron  Clinical  System  (Beckman  Coulter,  Inc.,  Pasadena,
CA,  USA)  using  the  bromocresol  purple  method.  Each  sam-
ple  was  analyzed  within  one  hour  of  being  drawn  and  the
equipment  was  calibrated  every  day  with  an  established
control.
The  endoscopic  lesions  responsible  for  bleeding  were
recorded.  The  endoscopic  therapy  used  was  based  on  the
Forrest  classiﬁcation,  which  stratiﬁes  patients  with  peptic
ulcer  disease  (the  most  common  cause  of  NVUGB)  into  high
and  low-risk  categories  for  mortality.  This  classiﬁcation  pre-
dicts  the  risk  of  rebleeding  and  is  the  standard  evaluation
method  of  the  endoscopic  intervention  modalities.14 The
Rockall  prognostic  score,  which  has  reported  usefulness  as
a  predictor  of  in-hospital  mortality,  was  also  used.15,16
The  procedures  were  performed  by  professors  or  resi-
dents  in  gastroenterology  involved  in  the  project.  Patients
had  daily  follow-up  visits  during  hospitalization  or  until
discharge  or  death.  All-cause  in-hospital  mortality  was  con-
sidered.  Approval  was  obtained  from  the  research  and  ethics
committee  of  the  School  of  Medicine  and  the  Hospital
Universitario  ‘‘Dr.  José  E.  González’’  of  the  Universidad
Autónoma  de  Nuevo  León. Informed  consent  was  obtained
from  all  participants  for  the  diagnostic  and  therapeutic
maneuvers  required  in  each  case.Statistical  analysis
Categorical  variables  were  expressed  in  percentage  fre-
quencies,  and  continuous  variables  as  means  and  standard
m
d
t
Ning  185
eviations.  ROC  curve  analysis  was  applied  to  evaluate  the
erformance  of  serum  albumin  and  the  Rockall  score  in
dentifying  mortality  in  patients  with  NVUGB,  as  well  as  to
etermine  the  optimal  operating  point  that  made  a  distinc-
ion  between  deceased  patients  and  survivors  with  respect
o  serum  albumin  upon  admission.  After  exploring  this  opti-
al  value  for  serum  albumin,  a  comparative  analysis  was
erformed  to  establish  the  differences  between  groups.
dds  ratios  were  determined  for  all  the  evaluated  varia-
les.  Categorical  and  continuous  variables  were  analyzed
ith  the  X2 and  Mann-Whitney  U  tests.  Statistical  analyses
ere  performed  using  the  SPSS  v17.0  (Chicago,  IL,  USA)  and
edCalc® for  Windows,  version  9.5.0.0  (MedCalc  Software,
ariakerke,  Belgium)  programs.
esults
uring  the  study  period,  444  patients  with  upper  gastroin-
estinal  bleeding  were  evaluated.  Bleeding  was  deemed  to
e  of  non-variceal  origin  in  235  of  the  patients.  Of  this  pop-
lation,  33  had  CLD,  7  were  diagnosed  with  some  form  of
ancer,  and  10  presented  with  ESRD.  They  were  excluded
rom  the  study.  A  ﬁnal  total  of  185  patients,  105  men  and
0  women  with  a  mean  age  of  59.1  ±  19.9  years,  were
ncluded.  Mean  serum  albumin  upon  admission  was  2.9  ±
.9  g/dl,  and  132  patients  (71.4%)  had  hypoalbuminemia  (<
.5  g/dl).  Overall  in-hospital  mortality  was  7.0%.  The  global
edical  and  endoscopic  ﬁndings,  as  well  as  outcomes,  are
hown  in  Table  1.  ROC  curve  analysis  was  performed  with
he  serum  albumin  value  upon  admission,  resulting  in  an
UROC  of  0.738.  A  value  of  3.1  g/dl  was  found  to  be  the
iscriminating  ﬁgure  between  deceased  patients  and  sur-
ivors  with  a  sensitivity  of  92.3%,  speciﬁcity  of  44.2%,  PPV
f  10.6%,  and  NPV  of  98.8%.  Based  on  this  serum  albumin  cut-
ff  value,  there  were  differences  in  the  clinical  endoscopic
ariables  and  outcomes  between  those  with  an  albumin
evel  ≥  3.2  g/dl  and  those  with  a  level  <  3.2  g/dl  (Table
).
We performed  a  secondary  data  analysis,  comparing  the
verall  performance  of  serum  albumin  upon  admission  and
he  Rockall  score  for  identifying  the  mortality  rate.  No
tatistical  difference  for  predicting  mortality  was  found
etween  the  serum  albumin  AUROC  (0.738)  and  the  total
ockall  score  (0.715)  (ﬁg.  1).
iscussion and conclusions
he  serum  albumin  level  in  the  setting  of  NVUGB  is  an  in-
ospital  mortality  marker.  To  the  best  of  our  knowledge,
here  is  only  one  previous  retrospective  analysis  that  speciﬁ-
ally  addresses  the  role  of  serum  albumin  levels  in  NVUGB9,
lthough  several  other  studies  have  reported  the  associa-
ion  of  hypoalbuminemia  and  mortality.4,10 This  is  the  ﬁrst
rospective  report  addressing  the  value  of  serum  albumin
pon  admission  as  a  risk  factor  for  in-hospital  mortality  in
atients  with  NVUGB.
Several  studies  have  shown  that  an  alteration  in  albu-
in  plasma  levels  has  prognostic  value  in  relation  to
ifferent  clinical  conditions  and  scenarios.6--8 Our  research
eam  recently  published  a  cohort  of  1,067  patients  with
VUGB  in  whom  a  serum  albumin  level  upon  admission  <
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Table  1  Results  of  patient  treatment  and  management.
Variable  n  =  185  (%)
Endoscopic  lesion  responsible  for  bleeding
Gastric  ulcers  -  n  (%)  61  (33.0)
Duodenal  ulcers  -  n  (%)  56  (30.0)
Both  -  n  (%)  6  (3.2)
Erosions  -  n  (%)  26  (14.0)
Mallory-Weiss  tear  -  n  (%)  17  (9.1)
Vascular  lesions  -  n  (%)  5  (2.7)
Other  -  n  (%)  10  (5.4)
Not found  -  n  (%) 4  (2.1)
Endoscopic  treatment 74  (40.0)
Epinephrine  injection  -  n  (%) 7  (3.7)
BICAP  only  -  n  (%)  5  (2.7)
Combination  therapy  -  n  (%)  57  (30.8)
Hemoclip  -  n  (%) 5  (2.7)
Medical  treatment
PPI  +  H2RB  -  n  (%)  3  (1.6)
H2RB  -  n  (%)  43  (23.2)
PPI -  n  (%)  139  (75.1)
Predictors
Deaths  -  n  (%)  13  (7.0)
Shocka -  n  (%)  4  (2.1)
Multiorgan  failure  -  n  (%)  9  (4.8)
Rebleeding  -  n  (%)  10  (5.4)
Surgical  treatment  -  n  (%)  6  (3.2)
Hospital  stay,  days  -  n  (%)  4.2  ±  4.3
Rockall  score  -  n  (%)  4.3  ±  2.2
Values are presented as mean ± standard deviation.
BICAP: bipolar coagulation; H2RB: histamine 2 receptor block-
ers; PPI: proton pump inhibitor.
a Shock deﬁned as mean arterial pressure less than 65 mmHg.
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Figure  1  ROC  curve  of  serum  albumin  values  upon  admission
and Rockall  score  for  prediction  of  mortality.  AUROC  Rock-
all score:  0.715,  AUROC  Albumin:  0.738,  difference  between
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of  the  Rockall  score  for  classifying  the  risk  for  in-hospital.6  g/dl,  the  Rockall  score,  the  presence  of  rebleeding,
nd  hospital  stay  duration  were  independent  predictors
f  in-hospital  mortality.10 However,  we  included  patients
ith  CLD,  ESRD,  and  neoplasia.  These  three  comorbidi-
ies  have  been  previously  identiﬁed  as  predictors  of  a  low
lbumin  level  and  poor  outcome.11--13 In  addition,  it  has
een  stated  that  serum  albumin  presents  oxidative  dam-
ge  in  cirrhosis  and  an  alteration  in  its  structure  and
urnover.12,17,18 ESRD  has  been  shown  to  have  a higher
isk  for  gastrointestinal  bleeding,  with  the  likely  contri-
ution  of  several  factors  (glomerular  ﬁltration  rate,  age,
elicobacter  pylori  infection,  and  albumin  level).19 Finally,
ypoalbuminemia  in  the  setting  of  malignancy  without  gas-
rointestinal  bleeding  has  been  extensively  associated  with
oor  survival.20
When  the  demographic  and  clinical  variables,  the  etiol-
gy  of  bleeding,  and  the  mortality  rate  in  our  population
ere  compared  with  other  studies  in  Italy  (PNED),5 Canada
RUGBE),21 the  United  States  (AIMS65),22 and  Spain,23 we
oted  that  our  patients  tended  to  be  younger  (59.1  ±
9.9  years)  than  those  in  the  Italian  PNED  (68  ±  16  years),
anadian  RUGBE  (66  ±  17  years),  American  (AIMS65)  (75
ears,  IQR1-3,  60-83),  and  Spanish  (68  ±  15  years)  stud-
es.  In  addition,  our  study  had  similar  results  in  regard
m
(
eUROCs:  0.023,  p  =  NS.
o  the  etiology  of  bleeding,  the  rebleeding  rate,  and
ospital  stay.  However,  overall  mortality  in  our  patients
as  higher  (7.0%  vs  PNED  4.5%,  RUGBE  5.4%,  AMIS65  3.2-
.7%,  and  the  Spanish  study  2.5-1%).  This  may  be  related
o  the  major  presence  of  hypoalbuminemia  (71.4%)  due
o  subclinical  comorbidities  such  as  CLD  caused  by  non-
lcoholic  steatohepatitis,24,25 the  presence  of  subclinical
alnutrition,  and  the  high  prevalence  of  comorbidity,  car-
iovascular  disease,  and  diabetes  in  our  group  (Table
).
When  comparing  our  cohort  with  a  previous  report  from
aiwan,9 we  also  found  that  our  patients  were  younger,  and
he  number  of  men  was  smaller.  However,  in  our  study,  sim-
lar  to  the  Taiwanese  study,  patients  with  normal  serum
lbumin  compared  with  patients  in  the  hypoalbuminemia
roup  were  older,  they  presented  with  a  major  prevalence
f  comorbidities,  lower  levels  of  hemoglobin,  and  elevated
lood  urea  nitrogen  and  creatinine  upon  admission.  In  addi-
ion,  these  patients  had  longer  hospital  stay,  greater  blood
ransfusion  requirements,  and  higher  rebleeding  and  mor-
ality  rates.  We  did  not  ﬁnd  any  difference  between  groups
n  the  type  of  endoscopic  lesion  responsible  for  bleed-
ng.
There  was  no  statistically  signiﬁcant  difference  when
lbumin  values  were  analyzed  and  compared  with  the  total
ockall  score.  This  could  suggest  that  serum  albumin  upon
dmission  has  a  clinical  value  as  a  marker  similar  to  thatortality  in  NVUGB  patients  without  CLD,  ESRD,  or  cancer
ﬁg.  1).  The  high  sensitivity  and  negative  predictive  value
nabling  those  patients  (with  a serum  albumin  ≥  3.2  g/dl)
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Table  2  Comparison  of  clinical  variables  and  outcomes  of  patients  with  distinct  serum  albumin  level  upon  admission.
Variables  Albumin
≥  3.2  g  /dl
n  =  78
Albumin
<  3.2  g  /dl
n  =  107
OR  (95%  CI)  P  value
Age,  years  50.9  ±  20  65.1  ±  17.6  -  0.001
Comorbidities
Number of  patients  with  comorbidities  -  n  (%)  29  (37.0)  67(62.6)  2.8  (1.5  --  5.1)  0.001
Number of  comorbidities  1.5  ±  0.8  1.7  ±  0.8  -  NS
Diabetes mellitus  -  n  (%)  16  (20.5)  39  (36.4)  2.2  (1.1  --  4.3)  0.019
Cardiovascular  disease  -  n  (%)  21  (27.0)  45  (43.0)  2.0  (1.1  --  3.8)  0.025
COPD -  n  (%) 3  (3.8) 9  (8.4)  -  NS
CKD (non  ESRD)  -  n  (%) 5  (6.4) 22  (20.6) 3.8  (1.4  --  10.5) 0.007
Risk factors
Use  of  NSAIDs  -  n  (%)  20  (25.6)  41  (38.3)  -  NS
History of  previous  GI  bleeding  -  n  (%)  6  (7.7)  10  (9.3)  -  NS
Laboratory variables  upon  admission
Hemoglobin  -  g/dl 11.3  ±  3.3  7.6  ±  2.8  -  0.001
BUN -  mg/dl 30.1  ±  27 47.1  ±  44.7  -  <0.001
Creatinine -  mg/dl 1.4  ±  1.2  1.7  ±  1.2  -  0.001
Endoscopic lesion  responsible  for  bleeding
Gastric  ulcers  -  n  (%)  23  (29.5)  37  (34.6)  -  NS
Duodenal ulcers  -  n  (%)  18  (23.1)  38  (35.5)  -  NS
Erosions -  n  (%)  13  (16.7)  12  (12.1)  -  NS
Clinical outcomes
Deaths  -  n  (%)  1  (1.3)  12  (11.2)  9.7  (1.2  --  76.5)  0.009
Shock -  n  (%)  0  (0.0)  4  (3.7)  -  NS
Multiorgan failure  -  n  (%)  1  (1.3)  8  (7.5)  -  NS
Rebleeding -  n  (%)  1  (1.3)  9  (8.0)  7.0  (0.9  --  56.0)  0.047
Hospital stay,  days  -  n  (%)  3.3  ±  4.3  4.9  ±  4.2  -  <0.001
Need for  transfusion  -  n  (%)  33  (42.3)  81  (75.7)  4.2  (2.3  --  8.0)  <0.001
Number of  transfused  units  1.9  ±  1  3.0  ±  1.9  -  0.001
Values are presented as mean ± standard deviation.
BUN: blood urea nitrogen; CI: Conﬁdence Interval; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; ESRD:
end-stage renal disease; GI: gastrointestinal; NS: not statistically signiﬁcant; NSAIDs: Nonsteroidal anti-inﬂammatory drugs; OR: Odds
ratio.
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twith  a  very  low  likelihood  of  poor  outcome  to  be  distin-
guished,  is  remarkable.
Even  though  albumin  plays  an  important  role  in  maintain-
ing  normal  physiologic  processes  and  it  has  been  described
as  a  marker  of  worse  prognosis,  treatment  with  its  replace-
ment  in  patients  with  hypoalbuminemia  has  not  led  to  better
survival  in  other  settings,  such  as  in  critically  ill  patients  and
those  with  sepsis.26,27 In  the  setting  of  peptic  ulcer  bleeding,
one  prospective  study  demonstrated  that  albumin  adminis-
tration  in  patients  with  hypoalbuminemia,  compared  with
a  control  group  (also  with  hypoalbuminemia),  shortens  the
duration  of  hospital  stay  (9  vs  15  days,  p  =  0.02).  However,
no  signiﬁcant  difference  was  found  in  the  rate  of  rebleeding
and  mortality.28 Therefore,  based  on  these  pieces  of  evi-
dence  and  given  the  higher  presence  of  comorbidity  in  the
hypoalbuminemia  group  in  our  study,  it  appears  that  albu-
min  itself  is  not  a  determinant  of  mortality,  but  a  surrogate
marker  of  a  worse  baseline  condition.
s
o
oOne  of  the  strengths  of  our  study  is  the  fact  that  it
s  a prospective  cohort  study  with  predeﬁned  inclusion
riteria  in  patients  with  NVUGB  receiving  early  endoscopic
herapy  that  do  not  have  evident  CLD,  ESRD,  or  cancer.  We
lso  found  that  the  serum  albumin  level  (<  3.2  g/dl)  upon
dmission  was  a  marker  of  increased  in-hospital  mortality.
he  main  limitations  of  our  study  were  that  we  did  not
valuate  the  nutritional  status  of  the  patients,  which  may
e  an  important  factor  causing  hypoalbuminemia,29 and  we
ere  not  able  to  assess  30-day  mortality,  which  may  have
esulted  in  an  underestimated  mortality,  since  the  overall
ospital  mortality  rate  was  not  signiﬁcantly  higher  than
hat  reported  in  other  studies.
In  conclusion,  hypoalbuminemia  appears  to  be  an  impor-
ant  surrogate  marker  of  poor  clinical  condition,  which
ubsequently  suggests  a  poor  outcome  in  NVUGB,  with  an
verall  performance  for  identifying  mortality  similar  to  that
f  the  Rockall  score.
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